Kenacort-T (Triamcinolone Acetonide)
Injectable Glucocorticoid for Arthritis, Allergies and Inflammatory Conditions
Quick Facts About Kenacort-T
Key Takeaways About Kenacort-T
- Long-acting injectable steroid: A single Kenacort-T injection provides anti-inflammatory relief lasting approximately 2 to 4 weeks, reducing the need for daily oral corticosteroid therapy
- Administered by healthcare professionals only: Kenacort-T is given as an intramuscular or intra-articular injection by a doctor or nurse using strict aseptic technique
- Not for children under 6: Due to the risk of severe allergic-type reactions and the presence of benzyl alcohol, Kenacort-T must not be given to children under 6 years, premature infants, or neonates
- Repeated use carries systemic risks: Long-term use with repeated injections can cause cataracts, osteoporosis, adrenal suppression, Cushingoid features, and elevated blood glucose
- Avoid live vaccines: Kenacort-T suppresses the immune system, so live vaccines should not be administered during treatment as they may cause infection rather than immunity
What Is Kenacort-T and What Is It Used For?
Kenacort-T contains the active substance triamcinolone acetonide, a potent synthetic glucocorticoid (corticosteroid) that works by suppressing the immune system and reducing inflammation throughout the body. It is given as an injection by a healthcare professional to treat conditions where powerful anti-inflammatory or immunosuppressive therapy is required.
Triamcinolone acetonide belongs to the class of fluorinated corticosteroids, which are among the most potent anti-inflammatory agents available in clinical medicine. Unlike naturally occurring cortisol produced by the adrenal glands, triamcinolone acetonide has been chemically modified to enhance its anti-inflammatory potency while reducing its tendency to cause sodium and water retention. This makes it particularly suitable for treating inflammatory and autoimmune conditions that require sustained suppression of the immune response.
Kenacort-T is formulated as an aqueous suspension intended for injection. The suspension formulation allows the drug to be slowly absorbed from the injection site, providing a prolonged duration of action of approximately 2 to 4 weeks from a single injection. This depot effect is a key advantage of Kenacort-T, as it eliminates the need for daily dosing and can provide consistent therapeutic levels over an extended period.
Approved Clinical Indications
Kenacort-T is indicated for the treatment of several conditions that require immune suppression or potent anti-inflammatory therapy:
- Rheumatoid arthritis: Reduces joint inflammation, swelling, pain, and stiffness in patients with active rheumatoid arthritis. Intra-articular injection can provide targeted relief in individual affected joints, while intramuscular injection offers systemic anti-inflammatory effects.
- Severe dermatological conditions: Used for inflammatory skin diseases that have not responded adequately to topical treatment, including severe eczema, psoriasis, pemphigus, and other steroid-responsive dermatoses.
- Allergic rhinitis: Provides effective relief of nasal congestion, sneezing, and rhinorrhoea in patients with seasonal or perennial allergic rhinitis when conventional treatments are insufficient.
- Allergic asthma: May be used as a short-term measure to control severe allergic asthma exacerbations, particularly when oral corticosteroids are impractical or when a depot injection offers better compliance.
The choice between intramuscular and intra-articular administration depends on the condition being treated. Intramuscular injection (typically into the gluteal muscle) provides systemic effects and is used for widespread inflammatory or allergic conditions. Intra-articular injection delivers the drug directly into an affected joint, providing localised anti-inflammatory action with reduced systemic exposure.
Triamcinolone acetonide, the active substance in Kenacort-T, may also be approved for additional conditions not listed above. Always follow your doctor's specific instructions regarding the use of this medication and consult a healthcare professional if you have questions about its suitability for your condition.
What Should You Know Before Receiving Kenacort-T?
Before receiving Kenacort-T, your doctor must evaluate your medical history, current medications, and overall health status. There are specific contraindications and precautions that must be considered to ensure safe use. Tell your doctor about all medical conditions, especially infections, diabetes, osteoporosis, and any plans for vaccination.
Contraindications
Kenacort-T must not be used in the following situations:
- Hypersensitivity: If you are allergic to triamcinolone acetonide or any of the other ingredients in Kenacort-T, including benzyl alcohol, carmellose sodium, polysorbate 80, or sodium chloride.
- Active systemic infections: Including tuberculosis and gonorrhoea. Corticosteroids suppress the immune system and can mask the signs of infection, allowing untreated infections to spread and potentially become life-threatening.
- Live vaccines: Patients receiving immunosuppressive doses of corticosteroids should not receive live or live-attenuated vaccines due to the risk of disseminated infection.
Warnings and Precautions
Inform your doctor before receiving Kenacort-T if you have any of the following conditions, as they may require special monitoring, dose adjustment, or alternative treatment:
- Osteoporosis: Corticosteroids accelerate bone loss and increase the risk of fractures. Your doctor may recommend calcium and vitamin D supplementation and bone density monitoring during prolonged treatment.
- Recent intestinal anastomosis: Corticosteroids may impair wound healing and increase the risk of anastomotic dehiscence (surgical connection breakdown) in the gastrointestinal tract.
- History of psychosis or psychiatric disorders: Corticosteroids can cause or exacerbate mood changes, depression, euphoria, insomnia, and in rare cases, frank psychosis. Patients with a history of psychiatric illness are at increased risk.
- Peptic ulcer disease: Active or history of gastric or duodenal ulcers, as corticosteroids may increase the risk of gastrointestinal bleeding and perforation.
- Latent tuberculosis: Corticosteroids can reactivate dormant tuberculosis infection. Your doctor may recommend preventive anti-tuberculosis therapy if you have a history of TB or a positive tuberculin test.
- Diabetes mellitus: Triamcinolone acetonide can increase blood glucose levels by promoting gluconeogenesis and reducing insulin sensitivity. Diabetic patients may require adjustment of their antidiabetic medication.
- Hypertension and heart failure: Although triamcinolone has relatively low mineralocorticoid activity, fluid retention and electrolyte imbalances may still occur, potentially worsening hypertension or heart failure.
- Active infections: Corticosteroids suppress immune function and may mask the symptoms of infection. Any concurrent infection must be adequately treated before or during corticosteroid therapy.
- Hepatitis B virus infection: History of or current hepatitis B infection, as corticosteroids may cause reactivation of the virus. Your doctor may wish to monitor you closely during and after treatment.
Contact your doctor immediately if you experience blurred vision or other visual disturbances during or after treatment with Kenacort-T. These symptoms may indicate serious ocular complications such as elevated intraocular pressure (glaucoma), cataracts, or central serous chorioretinopathy, which require prompt medical evaluation.
Children and Adolescents
Kenacort-T should be used with caution in growing children and adolescents. Prolonged or repeated corticosteroid therapy can suppress the hypothalamic-pituitary-adrenal (HPA) axis and impair linear growth. Children receiving Kenacort-T should be monitored regularly for growth velocity and adrenal function.
Kenacort-T must not be given to children under 6 years of age due to the risk of severe allergic-type reactions. Furthermore, this medication must not be administered to premature infants or neonates because it contains benzyl alcohol, a preservative that has been associated with fatal “gasping syndrome” in premature neonates characterised by metabolic acidosis, respiratory distress, and cardiovascular collapse.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, you must inform your doctor before receiving Kenacort-T. There is evidence from both animal studies and human observational data that corticosteroids administered during pregnancy may be associated with adverse foetal effects, including:
- Reduced birth weight and intrauterine growth restriction
- Risk of cleft palate (primarily observed with systemic corticosteroids in the first trimester)
- Neonatal adrenal suppression if the mother receives prolonged corticosteroid therapy
The decision to use Kenacort-T during pregnancy should be made only when the potential benefit to the mother outweighs the potential risk to the foetus. Corticosteroids are excreted in breast milk and may affect the infant. Discuss the risks and benefits of breastfeeding while receiving Kenacort-T with your doctor.
Driving and Operating Machinery
Kenacort-T may cause dizziness, which could impair your ability to drive or operate machinery. You should assess your own fitness to drive or perform tasks requiring alertness after receiving this injection. If you experience dizziness or any other side effects that affect your concentration, do not drive or operate machinery until these effects have resolved.
Important Information About Excipients
Benzyl alcohol: Kenacort-T contains 9.9 mg of benzyl alcohol per millilitre as a preservative. Benzyl alcohol may cause allergic reactions in some individuals. In premature infants and neonates, benzyl alcohol has been associated with serious and potentially fatal toxicity, including metabolic acidosis and respiratory failure. If you have impaired liver or kidney function, consult your doctor before receiving this medication, as large amounts of benzyl alcohol may accumulate and cause metabolic acidosis.
Sodium content: Kenacort-T contains less than 1 mmol (23 mg) of sodium per dose, meaning it is essentially sodium-free and is suitable for patients on a sodium-restricted diet.
How Does Kenacort-T Interact with Other Drugs?
Kenacort-T can interact with several classes of medications, potentially reducing their effectiveness or increasing the risk of side effects. Always inform your doctor about all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.
Drug interactions with corticosteroids are clinically significant because they can alter the metabolism of triamcinolone acetonide or change the therapeutic effect of concomitant medications. The most important interactions involve drugs that induce hepatic enzymes (which can reduce the effectiveness of Kenacort-T), vaccines (which may be rendered less effective or potentially dangerous), and medications whose effects are modified by corticosteroid-induced changes in metabolism.
Major Interactions
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| Rifampicin | Potent CYP3A4 inducer; significantly reduces triamcinolone blood levels and therapeutic effect | Dose increase may be needed; monitor clinical response closely |
| Phenytoin, Phenobarbital, Carbamazepine | Hepatic enzyme inducers that accelerate corticosteroid metabolism, reducing efficacy | Consider dose adjustment; monitor for loss of corticosteroid effect |
| Live vaccines (e.g. MMR, varicella, BCG, oral polio) | Risk of disseminated vaccine infection due to immunosuppression; reduced vaccine immunogenicity | Contraindicated during immunosuppressive therapy; wait appropriate interval after discontinuation |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Additive risk of gastrointestinal ulceration and bleeding | Use gastroprotective therapy if concurrent use is necessary |
| Oral anticoagulants (warfarin) | Corticosteroids may alter anticoagulant effect; increased bleeding risk with concurrent GI effects | Monitor INR more frequently; adjust anticoagulant dose as needed |
Minor Interactions
| Drug / Drug Class | Interaction Effect | Clinical Action |
|---|---|---|
| Antidiabetic agents (insulin, metformin, sulfonylureas) | Corticosteroids increase blood glucose; may counteract antidiabetic therapy | Monitor blood glucose closely; adjust antidiabetic medication as needed |
| Diuretics (furosemide, hydrochlorothiazide) | Additive potassium loss leading to hypokalaemia; increased risk of cardiac arrhythmias | Monitor serum potassium levels; consider potassium supplementation |
| Antihypertensives | Corticosteroid-induced fluid retention may reduce the effectiveness of antihypertensive agents | Monitor blood pressure; adjust antihypertensive dose if needed |
| Inactivated vaccines | Reduced immune response; vaccine may be less effective | Can be administered but immune response may be diminished; inform your vaccinator |
Always inform your doctor or pharmacist about all medications you are taking or have recently taken, including over-the-counter medicines, vitamins, herbal supplements, and any recent vaccinations. This information is essential for preventing potentially harmful drug interactions.
What Is the Correct Dosage of Kenacort-T?
Kenacort-T is administered exclusively by a healthcare professional as an intramuscular or intra-articular injection. The dose is individualised based on the condition being treated, the severity of symptoms, the patient's body weight, and the clinical response. There is no self-administration of this medication.
The dosage of Kenacort-T must be determined by the prescribing physician and tailored to each individual patient. As a depot injection, the drug is designed to provide sustained therapeutic levels, and the dosing interval is typically determined by the duration of clinical response rather than a fixed schedule. Strict aseptic technique is mandatory for all injections to prevent infection.
Adults
Intramuscular Injection (Systemic Use)
For systemic inflammatory and allergic conditions, the typical adult dose is 40 mg (1 mL) injected deep into the gluteal muscle. The injection should not be given subcutaneously, as this can cause local skin and fat atrophy. The dose may be repeated when clinically indicated, typically every 2 to 4 weeks, depending on the patient's response.
Intra-articular Injection (Joint Injection)
For joint inflammation, the dose depends on the size of the affected joint. Large joints (knee, hip, shoulder): 20–40 mg. Medium joints (elbow, wrist, ankle): 10–20 mg. Small joints (fingers, toes): 2.5–10 mg. Injections into the same joint should generally not be repeated more frequently than every 3 to 4 weeks.
Children (Over 6 Years)
Paediatric Dosing
For children aged 6 years and older, the dose is determined by the physician based on body weight, age, and the severity of the condition. Lower doses are generally used, and treatment duration should be kept as short as possible. Growth monitoring is essential during treatment, as systemic corticosteroids can suppress linear growth.
Kenacort-T must not be given to children under 6 years of age because they are at increased risk of severe allergic-type reactions. This medication must also not be given to premature infants or neonates due to the benzyl alcohol content.
Elderly Patients
Elderly patients may be more susceptible to the adverse effects of corticosteroids, particularly osteoporosis, hypertension, diabetes, and increased susceptibility to infections. The lowest effective dose should be used, and patients should be monitored closely for bone mineral density changes, blood glucose elevations, and signs of infection. Prophylactic measures against osteoporosis (calcium, vitamin D, and potentially bisphosphonates) should be considered for elderly patients receiving repeated injections.
Missed Dose
Since Kenacort-T is administered by a healthcare professional in a clinical setting, missed doses are managed by rescheduling the appointment. If you miss a scheduled injection, contact your doctor to arrange a new appointment. Do not attempt to compensate for a missed dose by receiving a double dose at the next visit.
Overdose
The likelihood of acute overdose with Kenacort-T is low because it is administered by healthcare professionals. In the unlikely event of accidental overdose, the risk of serious acute toxicity is minimal. Chronic overdose through excessively frequent injections can lead to Cushing's syndrome (characterised by weight gain, moon face, buffalo hump, muscle wasting, skin thinning, and easy bruising), adrenal suppression, osteoporosis, and metabolic complications. Treatment of chronic overdose involves gradual dose reduction under medical supervision.
Administration Instructions for Healthcare Professionals
Strict aseptic technique is mandatory for all injections. The vial must be shaken thoroughly before use to ensure a uniform suspension. Before withdrawing the suspension, it should be inspected for any granular or gritty appearance (agglomeration). Agglomeration occurs when the drug substance separates from the solution and appears as a white precipitate. An agglomerated product must be discarded and not used. After drawing up the suspension, inject without delay to prevent sedimentation in the syringe.
What Are the Side Effects of Kenacort-T?
Like all corticosteroids, Kenacort-T can cause side effects, although not everyone experiences them. Local injection-site reactions are the most common, while systemic side effects become more likely with repeated, long-term use. Serious allergic reactions, including breathing difficulties, can occur rarely and require immediate medical attention.
The side effects of Kenacort-T can be divided into two categories: effects that occur with single or short-term use, and effects that develop with prolonged treatment involving repeated injections. Local treatment (intra-articular injection) is less likely to cause systemic side effects than intramuscular injection, but they can still occur with repeated use.
Contact emergency services immediately if you experience signs of a severe allergic reaction (anaphylaxis) after receiving Kenacort-T, including difficulty breathing, swelling of the face, lips, tongue, or throat, severe rash or hives, rapid heartbeat, or feeling faint. Although uncommon, these reactions can be life-threatening and require emergency treatment.
Side Effects from Single or Short-Term Use
Common
- Local skin and soft tissue atrophy at the injection site (when injected subcutaneously or into soft tissue)
- Subcutaneous fat atrophy at the injection site (following intra-articular injection)
- Local irritation and pain at or around the injection site
Uncommon
- Allergic reactions, occasionally severe reactions that may cause difficulty breathing
- Dizziness
- Temporary facial flushing (erythema)
Side Effects from Prolonged Treatment (Repeated Injections)
With long-term use involving repeated injections, systemic absorption of triamcinolone acetonide can lead to a range of effects affecting multiple organ systems. These effects are more commonly associated with intramuscular injection but may also occur with repeated intra-articular injections.
Common
- Cataracts (posterior subcapsular cataracts)
Uncommon
- Blood clots (thromboembolism)
- Elevated intracranial pressure (pseudotumour cerebri)
- Elevated blood pressure (hypertension)
- Cushing's syndrome features (weight gain with central fat distribution, muscle weakness, easy bruising, acne, osteoporosis, mood changes)
- Adrenal suppression (reduced adrenal gland function)
- Elevated sodium levels (hypernatraemia)
- Low potassium levels (hypokalaemia)
- Elevated blood glucose (hyperglycaemia)
- Fluid retention (oedema)
- Avascular necrosis (death of bone tissue, particularly in the femoral head)
- Muscle atrophy (wasting)
- Psychiatric disturbances (mood swings, depression, euphoria, insomnia)
- Glaucoma (elevated intraocular pressure)
- Osteoporosis (bone thinning)
- Proximal myopathy (muscle weakness, particularly in the shoulders and hips)
- Menstrual irregularities
- Postmenopausal bleeding
- Impaired wound healing
- Negative nitrogen balance (excessive protein breakdown)
Not Known
- Reactivation of dormant infections (e.g. latent tuberculosis)
- Reduced immune function (increased susceptibility to infections)
- Unmasking or exacerbation of latent diabetes mellitus
- Blurred vision
- Reduced visual acuity
Additional Side Effects in Children
In children receiving prolonged corticosteroid treatment, growth suppression may occur. This is because corticosteroids inhibit the growth hormone axis and can reduce collagen synthesis and bone formation in growing bones. Growth velocity should be monitored in all children receiving repeated Kenacort-T injections, and the minimum effective dose should always be used.
It is important to report suspected adverse reactions after a medicine has been authorised. This allows ongoing monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients can report suspected adverse reactions to their national pharmacovigilance authority.
How Should Kenacort-T Be Stored?
Kenacort-T must be stored at controlled room temperature between 15°C and 25°C (59°F to 77°F). Protect from cold and do not freeze. Keep the vial in its original packaging to protect from light, and store in an upright position. Shake the vial before each use.
Proper storage of Kenacort-T is essential to maintain the stability and efficacy of the suspension. The product should be kept out of the sight and reach of children at all times. The following storage conditions must be strictly observed:
- Temperature: Store between 15°C and 25°C (59°F to 77°F). Do not refrigerate or freeze, as freezing can permanently alter the suspension and render the product unusable.
- Light protection: Keep the vial in its original carton to protect from light exposure, which can degrade the active substance.
- Position: Store the vial in an upright position to ensure proper settling of the suspension.
- Before use: Shake the vial thoroughly before each use to ensure a uniform suspension. Inspect visually for any signs of agglomeration (clumping), discolouration, or foreign particles before use.
Do not use Kenacort-T after the expiry date printed on the label after “EXP”. The expiry date refers to the last day of the stated month. Do not dispose of medications via the sewer system or household waste. Return unused or expired medication to your pharmacy for safe disposal to help protect the environment.
What Does Kenacort-T Contain?
Each millilitre of Kenacort-T suspension for injection contains 40 mg of the active ingredient triamcinolone acetonide, along with several inactive ingredients (excipients) that maintain the stability, pH, and sterility of the formulation.
Active Ingredient
The active substance is triamcinolone acetonide at a concentration of 40 mg per millilitre. Each vial contains 1 mL of suspension, providing a total of 40 mg of triamcinolone acetonide per vial.
Inactive Ingredients (Excipients)
The other ingredients are:
- Carmellose sodium (carboxymethylcellulose sodium) – a suspending agent that helps maintain the uniform distribution of the active substance in suspension
- Sodium chloride – used to adjust tonicity (osmolality) to make the injection compatible with body fluids
- Polysorbate 80 – a surfactant that aids in wetting and dispersing the active substance
- Benzyl alcohol (9.9 mg/mL) – a preservative to prevent microbial contamination
- Sodium hydroxide – used for pH adjustment
- Hydrochloric acid – used for pH adjustment
- Water for injections – the aqueous vehicle
Product Appearance and Packaging
Kenacort-T is a white to off-white aqueous suspension supplied in a glass vial. Each carton contains one vial with 1 mL of suspension for injection. Before use, the vial must be shaken to produce a uniform suspension. The suspension should not be used if agglomeration (clumping of particles) is observed.
How Does Kenacort-T Work in the Body?
Kenacort-T works by delivering triamcinolone acetonide, a potent synthetic glucocorticoid that suppresses inflammation and immune function at the molecular level. It binds to glucocorticoid receptors inside cells, modifying gene expression to reduce the production of inflammatory mediators. Its depot formulation provides sustained release from the injection site over 2 to 4 weeks.
Triamcinolone acetonide exerts its effects through a well-characterised molecular mechanism common to all glucocorticoids, but with certain structural features that enhance its anti-inflammatory potency. As a fluorinated corticosteroid, it has been modified with a fluorine atom at the 9-alpha position and an acetonide group at the 16,17-position, which increases its binding affinity for the glucocorticoid receptor and reduces its mineralocorticoid activity (i.e. less tendency to cause sodium and water retention compared to cortisol or prednisolone).
Mechanism of Action
Upon entering cells, triamcinolone acetonide binds to the intracellular glucocorticoid receptor (GR), a member of the nuclear receptor superfamily. The drug-receptor complex then translocates to the cell nucleus, where it modulates gene transcription through two principal mechanisms:
- Transactivation: The GR complex binds to specific DNA sequences called glucocorticoid response elements (GREs) in gene promoter regions, upregulating the expression of anti-inflammatory proteins. These include lipocortins (annexins), which inhibit phospholipase A2 and thereby reduce the synthesis of pro-inflammatory prostaglandins and leukotrienes from arachidonic acid.
- Transrepression: The GR complex interacts with and inhibits transcription factors such as NF-kappaB and AP-1, which are key regulators of pro-inflammatory cytokine production. This results in reduced synthesis of interleukin-1 (IL-1), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), and other inflammatory mediators.
The combined effect of these molecular actions produces potent anti-inflammatory, immunosuppressive, and anti-allergic effects. Corticosteroids reduce capillary permeability (decreasing oedema), stabilise lysosomal membranes (preventing release of destructive enzymes), reduce leukocyte migration to inflamed sites, and suppress lymphocyte proliferation and antibody production.
Pharmacokinetic Profile
The pharmacokinetics of Kenacort-T are largely determined by its depot formulation. Following intramuscular injection, triamcinolone acetonide is slowly absorbed from the injection site as the crystalline suspension gradually dissolves. This provides sustained systemic levels of the drug over approximately 2 to 4 weeks, eliminating the peaks and troughs associated with oral dosing.
Triamcinolone acetonide has a biological half-life of 18 to 36 hours, which is considerably longer than its plasma half-life. This is because the drug's biological effects persist after plasma levels have declined, owing to the genomic mechanism of action that involves changes in gene expression. The drug is primarily metabolised in the liver and excreted via the kidneys.
Following intra-articular injection, the drug is deposited directly in the joint space, where it exerts potent local anti-inflammatory effects. Systemic absorption from the joint occurs gradually, which means that intra-articular administration provides relatively higher local concentrations with lower systemic exposure compared to intramuscular injection. However, significant systemic absorption can still occur, particularly with repeated injections or injections into highly vascular tissues.
Frequently Asked Questions About Kenacort-T
Kenacort-T (triamcinolone acetonide) is an injectable corticosteroid used to treat rheumatoid arthritis, certain skin conditions, allergic rhinitis, and allergic asthma. It works by suppressing the immune system and reducing inflammation. The injection is given either into a muscle (intramuscular) or directly into a joint (intra-articular), and its effects typically last 2 to 4 weeks.
The most common side effects of Kenacort-T include local skin and soft tissue atrophy at the injection site, subcutaneous fat atrophy (when injected into a joint), and local irritation or pain at the injection site. With repeated long-term use, systemic effects such as cataracts, elevated blood pressure, Cushing's syndrome symptoms, osteoporosis, and muscle weakness may occur. Uncommon side effects include allergic reactions, dizziness, and temporary facial flushing.
A single Kenacort-T injection typically provides relief for approximately 2 to 4 weeks. The duration of effect depends on the dose administered, the site of injection (intramuscular vs. intra-articular), and the individual patient's metabolism. Some patients may experience relief for up to 6 weeks. Your doctor will determine the appropriate interval between injections based on your clinical response.
Kenacort-T should not be given to children under 6 years of age due to the risk of severe allergic-type reactions. It must not be administered to premature infants or neonates because it contains benzyl alcohol, which can cause serious adverse effects in this population. In children over 6 years, it should be used with caution as prolonged corticosteroid treatment may suppress growth. Growth should be monitored regularly in children receiving this medication.
Kenacort-T should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Animal studies and human observational data suggest a risk of adverse foetal effects, including reduced birth weight and potential adrenal suppression in the newborn. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits with your doctor before receiving this injection. Your doctor may recommend alternative treatments during pregnancy.
Live vaccines (such as MMR, varicella, BCG, and oral polio) should be avoided while you are receiving Kenacort-T, as the immunosuppressive effect of the corticosteroid may reduce the vaccine's efficacy and increase the risk of infection from the live vaccine organism. Inactivated vaccines can generally be given, but their immune response may be diminished. Always inform your doctor that you have received Kenacort-T before undergoing any vaccination.
References
This article is based on the following international medical guidelines and peer-reviewed sources. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews of randomised controlled trials.
- Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases. 2023;82(1):3–18. doi:10.1136/ard-2022-223356
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021;73(7):924–939. doi:10.1002/acr.24596
- National Institute for Health and Care Excellence (NICE). Rheumatoid arthritis in adults: management. NICE guideline [NG100]. Updated 2023.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
- European Medicines Agency (EMA). Triamcinolone acetonide – Summary of Product Characteristics. EMA product information database. Accessed January 2026.
- Derendorf H, Mollmann H, Gruner A, et al. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clinical Pharmacology & Therapeutics. 1986;39(3):313–317.
- Hoes JN, Jacobs JWG, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases. 2007;66(12):1560–1567.
- British National Formulary (BNF). Triamcinolone acetonide. NICE BNF monograph. Accessed January 2026.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a group of licensed specialist physicians with expertise in rheumatology, dermatology, and clinical pharmacology.
Medical Writers
Board-certified physicians specialising in rheumatology, dermatology and clinical pharmacology with documented academic and clinical experience.
Medical Reviewers
Independent review board ensuring clinical accuracy, adherence to international guidelines (EULAR, ACR, NICE, WHO), and evidence level 1A standards.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.